产品目录 [{"id":"461","name":"Evaluation of Parsaclisib plus Rituximab or Obinutuzumab in patients with Lymphoma that has stopped responding to treatment","price":1,"sku":"lymphoma-trial-4","brand":false,"position":10,"category":"Medicines\/Oncology\/Lymphoma"},{"id":"460","name":"Evaluation of Tafasitamab plus Parsaclisib in patients with Non Hodgkin Lymphoma or Chronic Lymphocytic Leukemia","price":1,"sku":"lymphoma-leukemia-trial-1","brand":false,"position":11,"category":"Medicines\/Oncology\/Lymphoma"},{"id":"447","name":"Rylaze","price":18330.59,"sku":"Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn)","brand":"Jazz Pharmaceuticals","position":12,"category":"Medicines\/Oncology\/Lymphoma"},{"id":"437","name":"Zynlonta","price":27746.55,"sku":"Zynlonta (loncastuximab tesirine-lpyl)","brand":"ADC Therapeutics","position":13,"category":"Medicines\/Oncology\/Lymphoma"},{"id":"434","name":"Xalkori","price":4927.62,"sku":"Xalkori (crizotinib)","brand":"Pfizer Limited","position":14,"category":"Medicines\/Oncology\/Lymphoma"},{"id":"416","name":"Ukoniq","price":1,"sku":"Ukoniq (umbralisib)","brand":"TG Therapeutics","position":15,"category":"Medicines\/Oncology\/Lymphoma"},{"id":"365","name":"Xpovio","price":67114.62,"sku":"Xpovio (selinexor)","brand":"Karyopharm","position":16,"category":"Medicines\/Oncology\/Lymphoma"},{"id":"357","name":"Monjuvi","price":4160,"sku":"Monjuvi (tafasitamab-cxix)","brand":"MorphoSys AG","position":17,"category":"Medicines\/Oncology\/Lymphoma"},{"id":"356","name":"Velexbru","price":1,"sku":"Velexbru (tirabrutinib hydrochloride)","brand":"Ono Pharmaceutical Co., Ltd.","position":18,"category":"Medicines\/Oncology\/Lymphoma"}]

淋巴瘤的治疗方案

淋巴瘤是三种主要的血癌之一,另外两种是白血病和骨髓瘤。血癌是一种影响血细胞生成和功能的癌症。根据血细胞的类型和受影响的方式,有几种不同类型的血癌。癌症通常开始于骨髓,那里的血液是由干细胞产生的。骨髓中的干细胞成熟并发展成三种类型的血细胞:红细胞、白细胞或血小板。在大多数血癌中,正常的血细胞发育过程被一种异常类型的血细胞不受控制地生长所打断。这些异常的血细胞...阅读更多 " 阻止血液发挥其许多常规功能,如抵御感染或防止严重出血。每种类型的血癌发病率都不同,有些非常常见,有些则相当罕见。2012年,非霍奇金淋巴瘤在全世界有38.6万个新病例,是所有癌症中第10大最常见的类型,其次是白血病,有35.2万个新病例。2012年,多发性骨髓瘤和霍奇金淋巴瘤是全球第23位和第25位最常见的癌症,分别有11.4万和6.6万个新病例。淋巴瘤是最常见的血癌类型,当被称为淋巴细胞(一种白血球)的免疫系统细胞不受控制地生长和繁殖时就会发生。它的两种主要形式是霍奇金淋巴瘤(HL)和非霍奇金淋巴瘤(NHL),后者比前者更常见。根据白血球的哪种机制受到影响,癌症可以以几种不同的方式发展,在HL和NHL中可以区分出几个亚类。淋巴瘤可在身体的许多部位发展,包括淋巴结、脾脏、骨髓、血液或其他器官。 霍奇金淋巴瘤和非霍奇金淋巴瘤-HL,也被称为霍奇金病,比NHL少见。虽然HL可以发生在儿童和成人身上,但它最常被诊断为20至343岁的年轻成人。2012年全球HL的发病率为66,0002。超过80%的HL患者存活5年,许多人被治愈。大多数接受HL治疗的患者将接受某种形式的化疗,有时也接受放疗作为他们的第一种治疗。滤泡性淋巴瘤是一种发展缓慢的NHL,占B细胞NHL的12%。症状包括淋巴结肿大、疲劳、呼吸急促、盗汗和体重减轻。许多患者在诊断时并没有表现出任何明显的症状。虽然它主要是一种缓慢生长的淋巴瘤,但滤泡性淋巴瘤有时也会演变成一种侵略性的形式。
查看 网格 列表

29项中的13-24

设置下降方向
进一步了解淋巴瘤的最新治疗方法
美国 0